Bottom Line: The U.S. Preventive Services Task Force (USPSTF) has updated and changed its recommendation on low-dose aspirin use to prevent cardiovascular disease (CVD). The USPSTF now recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults 60 years or older. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults ages 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Those who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. The USPSTF also has concluded the evidence is unclear whether aspirin use reduces the risk of colorectal cancer incidence or death. The USPSTF routinely makes recommendations about the effectiveness of preventive care services and this recommendation replaces the 2016 USPSTF recommendation on aspirin use to prevent CVD and colorectal cancer.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2022.4983)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Note: More information about the U.S. Preventive Services Task Force, its process, and its recommendations can be found on the newsroom page of its website.
# # #
Media advisory: To contact the U.S. Preventive Services Task Force, email the Media Coordinator at Newsroom@USPSTF.net or call 301-951-9203. The full report and related articles are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time and all USPSTF articles remain free indefinitely https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.4983?guestAccessKey=5f8d1e4c-6e91-4cf3-bc4a-fef906585c45&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=042622
Journal
JAMA